BenevolentAI Investor Day Presentation Deck slide image

BenevolentAI Investor Day Presentation Deck

Our Precision Medicine approaches are applied to multiple stages of our pipeline and can support repurposing activities Precision Medicine enabled Target ID Target Identification Hyp Gen & Hyp Val Hit ID & Expansion Discovery Lead Op Candidate Seeking Indication mapping Preclinical Repurposing a target or drug (approved or in development) through the identification of additional disease indications Address additional unmet need Maximise the value of a target or drug programme Identifying key patient cohorts and responders for drugs Optimise clinical development Increase probability of success Improve outcomes for patients Development Phase I Phase II Phase III Approval & Launch Identification of patient cohorts & responders Phase IV Additional indications Commercial & Lifecycle Optimised trial design & patient outcomes for each indication Benevolent 63
View entire presentation